Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)
This study will be conducted to evaluate the efficacy of Bendamustine Plus Rituximab (BR) in patients with relapsed or progressive Marginal Zone B-cell Lymphoma (MZBCL).
Marginal Zone B-cell Lymphoma
DRUG: bendamustine plus rituximab
Overall response rate based on Revised Response Criteria for Malignant Lymphoma, 6 months
Complete remission rate, 6 months|Safety based on NCI CTCAE version 4.0, 1 year
Multi-center trial, Phase II, non-randomized, open-label, single-arm study with combined therapy of bendamustine and rituximab in patients with MZBCL who has relapsed or progressive to prior chemotherapy or chemo-radiotherapy.